NCT00001341View on ClinicalTrials.gov

A Phase I Trial of ZD1694 (TOMUDEX), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

September 30, 1993

Study Completion Date

June 30, 2001

Conditions

Neoplasm

Interventions

DRUG

ZD1694 (TOMUDEX)

Trial Locations (1)

20892

National Cancer Institute (NCI), Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH